Evidence Table H3: DISCRETE outcomes for class ANTI-BACTERIAL (ORAL).

Trial # Method Info	Compar-ison	Discrete Outcome Name (Units) Definition/Comments	Follow-up (wks)	Treatment Attribute: Number of patient	Comparator Attribute: Number of patients	Between P-value
	H.01.01			**Clindamycin**	**Vehicle**	
56 Parallel Mod/sev N=98		**Side effects**	Long (13	Severe diarrhea (withdraw) 1 Mild diarrhea 8 Stomach gas 1 Stomach ache (mild) 0	Severe diarrhea (withdraw) 0 Mild diarrhea 1 Stomach gas 0 Stomach ache (mild) 1	
				Heartburn (mild) 1 Urinary frequency (mild) 0 morbilliform rash (withdraw) 1	Heartburn (mild) 0 Urinary frequency (mild) 1 Morbilliform rash (withdraw) 0	
	H.01.02			**Clindamycin**	**Tetracycline**	
265 ↑ Parallel Mod N=48		**Esophagitis**	Mid (8)	Present 1 Absent 24	Present 0 Absent 23	
		Mild diarrhea and cramping	Mid (8)	Present 1 Absent 24	Present 0 Absent 23	
		Overall change/physician	Mid (8)	Much improved 13 Improved 9 Same 3 Worse 0	Much improved 16 Improved 6 Same 1 Worse 0	
	H.01.02			**Clindamycin hydrochloride**	**Tetracycline hydrochloride**	
275 ↓ Parallel Sev N=47		**Overall change/patient (vas)**	Mid (10.	Worse 0 Same 1 Improved 12 Much improved 1	Worse 0 Same 1 Improved 13 Much improved 2	
		Diarrhea	Mid (11)	Withdraw 2	Withdraw 0	
		Lesions change	Mid (11)	25% or less decrease 2 More than 25% decrease 12	25% or less decrease 2 More than 25% decrease 14	
	H.02.01			**Demethylchlortetracycline**	**Placebo**	
162 ↑ Parallel Mod/sev N=37		**Adverse effects**	Mid (9)	Photosensitivity 11 GI disturbance 2 Photo-onycholysis 2	Photosensitivity 0 GI disturbance 0 Photo-onycholsis 0	**0.01**

TRIAL: ↑↓ -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method Info	Compar-ison	Discrete Outcome Name (Units) Definition/Comments	Follow-up (wks)	Treatment Attribute: Number of patient	Comparator Attribute: Number of patients	Between P-value
162 ↑ Parallel Mod/sev N=37		**Severity change**	Mid (9)	Excellent or good 16 Poor 5	Excellent or good 5 Poor 11	**0.01**
192 Parallel N=74		**Overall change/physician**	Short (3)	Good 29 Fair 3 Poor 5 Questionable 3	Good 23 Fair 5 Poor 3 Questionable 3	**NS**
193 Cross-over N=74		**Overall change/physician, patient**	Short (3)	Declo preferred 20 Placebo preferred 6 Equally good 7 Neither good 3 Questionable 1	Declo preferred 20 Placebo preferred 6 Equally good 7 Neither good 3 Questionable 1	**0.01**
312 ↑ Parallel Mild/mod/sev N=66		**Overall change/physician**	Short (4)	Improved 5 No change 10 Worse 0 Not assessed 3	Improved 3 No change 13 Worse 0 Not assessed 6	**NS**
	H.02.01			**Demethylchlortetracycline**	**Vehicle**	
71 Cross-over N=150		**Severity change**	Short (4)	Worse 8 No change after good response 3 No change 5 Slight 11	Worse 10 No change after good response 2 No change 9 Slight 11	**NS**
		Side effects	Short (4)	Good 4 Excellent 11 Photoreactivity 15	Good 7 Excellent 3 Photoreactivity 1	
	H.02.02			**Demethylchlortetracycline**	**Phenethicillin**	
312 ↑ Parallel Mild/mod/sev N=66		**Overall change/physician**	Short (4)	Improved 5 No change 10 Worse 0 Not assessed 3	Improved 5 No change 10 Worse 1 Not assessed 4	**NS**
	H.02.03			**Demethylchlortetracycline**	**Tetracycline hydrochloride**	

TRIAL: ↑↓ -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method Info	Compar-ison	Discrete Outcome Name (Units) Definition/Comments	Follow-up (wks)	Treatment Attribute: Number of patient	Comparator Attribute: Number of patients	Between P-value
71 Cross-over N=150		**Severity change**	Short (4)	Worse 8 No change after good response 3 No change 5 Slight 11	Worse 10 No change after good response 3 No change 6 Slight 15	**NS**
				Good 4 Excellent 11	Good 4 Excellent 3	
		Side effects	Short (4)	Photoreactivity 15	Photoreactivity 3	
	H.02.03			**Demethylchortetracycline**	**Tetracycline**	
70 ↑ Parallel N=100		**Overall change/physician**	Long (13	Poor 0 Fair 1 Good 21 Excellent 12	Poor 0 Fair 3 Good 28 Excellent 19	**0.01**
		Side effects	Long (13	Diarrhea 0 Nausea 0 Pruritus ani 0	Diarrhea 4 Nausea 1 Pruritus ani 1	**0.05**
		Relapse	Long (15	Relapse 0	Relapse 8	
	H.03.01			**Doxycycline**	**Placebo**	
273 ↓ Cross-over Mild N=62		**Comedones (discretized %)**	Short (4)	Poor 47 Better than poor 15	Poor 47 Better than poor 15	
		Cysts	Short (4)	Good/excellent 16 Fair/poor/worse 46	Good/excellent 11 Fair/poor/worse 51	
		Inflammatory (discretized %)	Short (4)	Excellent 8 Good 13 Fair 7 Poor 20	Excellent 4 Good 11 Fair 5 Poor 21	
		Papules change	Short (4)	Worse 14 Good/excellent 26 Fair/poor/worse 36	Worse 21 Good/excellent 12 Fair/poor/worse 50	
		Pustules	Short (4)	Good/excellent 25 Fair/poor/worse 37	Good/excellent 15 Fair/poor/worse 47	

TRIAL: ↑↓ -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method Info	Compar-ison	Discrete Outcome Name (Units) Definition/Comments	Follow-up (wks)	Treatment Attribute: Number of patient	Comparator Attribute: Number of patients	Between P-value
273 ↓ Cross-over Mild N=62		**Side effects**	Short (4)	Diarrhea 0 Nausea 0 Photoxicity 0	Diarrhea 0 Nausea 0 Photoxicity 0	
	H.03.02			**Doxycycline**	**Fusidic acid cream**	
1 ↑ Parallel Mild/mod N=110		**Overall change/investigator**	Mid (10)	Cured 14 Improved 19 No effect 14	Cured 18 Improved 29 No effect 9	
		Overall change/patient	Mid (10)	Cured 14 Improved 19 No effect 14	Cured 16 Improved 30 No effect 10	**NS**
		Side effects	Mid (10)	Unpleasant smell 0 Smarting of eyes 0 Discontinued due to nausea 1 None 46	Unpleasant smell 2 Smarting of eyes 2 Discontinued due to nausea 0 None 52	
	H.03.04			**Doxycycline**	**Minocycline**	
311 Parallel Mild/mod N=18		**Side effects**	Mid (12)	GI pain/nausea 2 Constipation 1 Tired 1 None 4	GI pain/nausea 0 Constipation 0 Tired 0 None 8	
	H.03.04			**Doxycycline + placebo**	**Minocycline + placebo**	
257 Parallel Mod/sev N=79		**Withdrawal due to side effects**	Mid (12)	Dyspepsia 1 Headache 1 Nausea 0 Vertigo 0	Dyspepsia 1 Headache 0 Nausea 1 Vertigo 1	
	H.04.03			**Erythromycin**	**Tetracycline**	
6 ↑ Parallel N=40		**Severity change**		Very good 10 Good 3 Moderate 4 Poor 3	Very good 8 Good 10 Moderate 1 Poor 1	

TRIAL: ↑↓ -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method Info	Compar-ison	Discrete Outcome Name (Units) Definition/Comments	Follow-up (wks)	Treatment Attribute: Number of patient	Comparator Attribute: Number of patients	Between P-value
6 ↑ Parallel N=40		**Side effects**		Diarrhea 0 Nausea 1 Pruritus ani 0 Vomiting 1	Diarrhea 1 Nausea 1 Pruritus ani 1 Vomiting 0	
	H.04.03			**Erythromycin + placebo**	**Tetracycline + placebo**	
125 ↑ Parallel Mild/mod N=178		**Side effects**		Side effects leading to withdrawal 7 GI distress 4 Vaginal candidiasis 0 Pseudotumor cerebri 0	Side effects leading to withdrawal 2 GI distress 4 Vaginal candidiasis 1 Pseudotumor cerebri 1	
				Rash 1	Rash 0	
		Overall change/patient	Mid (12)	Improved or markedly improved 77 Worse or unchanged 23	Improved or markedly improved 89 Worse or unchanged 11	**NS**
	H.04.03			**Erythromycin acistrate**	**Tetracycline**	
36 ↑ Parallel Mod/sev N=60		**Side effects**	Mid (12)	Any event 11 None 18	Any effect 9 None 20	
		Side effects	Long (24	Any effect 3 None 18	Any effect 3 None 18	
	H.04.05			**Roxithromycin (150)**	**Roxithromycin (300)**	
4 ↑ Parallel N=30		**Severity change (akamatsu)**	Mid (8)	Worsening 2 No change 1 Slight improvement 1 Moderate improvement 10	Worsening 0 No change 2 Slight improvement 2 Moderate improvement 7	
				Good improvement 1	Good improvement 4	
	H.04.06			**Oleandomycin**	**Triacetyl-oleandomycin**	
247 Parallel N=142		**Overall change/physician**	Short (6)	Excellent 11 Good 23 Negative 19	Excellent 28 Good 44 Negative 17	
	H.05.01			**Minocycline**	**Placebo**	
161 ↑ Cross-over N=43		**Side effects**	Short (5)	Vertigo (withdraw) 1 Urticaria (withdraw) 1	Vertigo (withdraw) 0 Urticaria (withdraw) 0	

TRIAL: ↑↓ -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method Info	Compar-ison	Discrete Outcome Name (Units) Definition/Comments	Follow-up (wks)	Treatment Attribute: Number of patient	Comparator Attribute: Number of patients	Between P-value
	H.05.02			**Minocycline**	**Clindamycin**	
268 ↑ Parallel Mod/sev N=80		**Overall change/patient**	Mid (12)	Much improved/ improved 37 Not changed/ worse/ much worse 1	Much improved/improved 40 Not changed/ worse/ much worse 2	
		Side effects	Mid (12)	Facial allergy (withdraw) 0 Urticaria (withdraw) 1 Impetiginisation 0 Dryness 0 Diarrhea/ ahd 1	Facial allergy (withdraw) 1 Urticaria (withdraw) 0 Impetiginisation 1 Dryness 1 Diarrhea/ ahd 0	
	H.05.02			**Minocycline + placebo**	**Clindamycin phosphate + placebo**	
307 ↑ Parallel Mod/sev N=64		**Facial stinging**	Mid (12)	Present 1	Present 1	
	H.05.04			**Minocycline**	**Tetracycline**	
72 ↑ Parallel Mod/sev N=100		**Side effects**	Long (19	Vaginal candidiasis (withdraw) 1 Persistent headache (withdraw) 1 Dizzy/loss of vision (withdraw) 0	Vaginal canididiasis (withdraw) 1 Persistent headache (withdraw) 0 Dizzy/loss of vision (withdraw) 1	
298 Parallel Mod/sev N=62		**GI symtoms**	Mid (12)	Mild nausea 1 Moderate nausea 1 Moderate pain 0 None 28	Mild nausea 2 Moderate nausea 0 Moderate pain 1 None 29	
		Vaginal infection	Mid (12)	Mild 0 Moderate 0 None 30	Mild 2 Moderate 2 None 28	**NS**
	H.06.01			**Oxytetracycline**	**Placebo**	
250 Cross-over Mod/sev N=76		**Side effects**		Present 0	Present 0	

TRIAL: ↑↓ -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method Info	Compar-ison	Discrete Outcome Name (Units) Definition/Comments	Follow-up (wks)	Treatment Attribute: Number of patient	Comparator Attribute: Number of patients	Between P-value
250 Cross-over Mod/sev N=76		**Severity change [phase i]**	Mid (10)	Excellent 31 Good 20 Fair 3 Poor 1 Unchanged 0	Excellent 1 Good 5 Fair 10 Poor 5 Unchanged 0	
		Severity change [phase ii]	Mid (10)	Excellent 13 Good 7 Fair 1 Poor 0 Unchanged 0	Excellent 2 Good 8 Fair 25 Poor 13 Unchanged 4	
	H.06.02			**Oxytetracycline (oral) + vehicle**	**Benzoyl peroxide + placebo (oral)**	
255 Parallel Mod N=69		**Side effects**	Mid (12)	Severe facial reaction 0 GI symptoms 2 Vaginal candidiasis 0	Severe facial reaction 1 GI symptoms 2 Vaginal candidiasis 1	
	H.06.03			**Oxytetracycline + vehicle**	**Benzoyl peroxide + metronidazole + placebo**	
123 Parallel Mod/sev N=52		**Overall change/patient**	Short (6)	Much worse 0 Worse 1 Unchanged 3 Somewhat improved 4 Improved 6 Much improved 9	Much worse 0 Worse 0 Unchanged 1 Somewhat improved 2 Improved 8 Much improved 12	**NS**
		Overall change/physician	Short (6)	0-25% 2 26-50% 4 51-75% 6 76-100% 11	0-25% 1 26-50% 2 51-75% 8 76-100% 12	**NS**
		Severity change/photo	Short (6)	0-25% 3 26-50% 4 51-75% 4 76-100% 12	0-25% 1 26-50% 3 51-75% 10 76-100% 9	**NS**
	H.06.05			**Oxytetracycline (oral) + vehicle**	**Tetracycline (topical) + placebo (oral)**	
255 Parallel Mod N=69		**Side effects**	Mid (12)	Severe facial reaction 0 GI symptoms 2 Vaginal candidiasis 0	Severe facial reaction 0 GI symptoms 2 Vaginal candidiasis 0	

TRIAL: ↑↓ -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method Info	Compar-ison	Discrete Outcome Name (Units) Definition/Comments	Follow-up (wks)	Treatment Attribute: Number of patient	Comparator Attribute: Number of patients	Between P-value
	H.06.06			**Oxytetracycline**	**Trimethoprim + sulfamethoxazole**	
152 ↑ Parallel Mild/mod/sev N=16		**Overall change/matched (vas)**	Short (4)	Co-tri better 3 Oxytet better 2 Both the same 2	Co-tri better 3 Oxytet better 2 Both the same 2	**NS**
		Inter-treatment severity comparison	Mid (12)	Papules 2 Pustules 2	Papules 6 Pustules 6	
		Overall change/matched (vas)	Mid (12)	Co-trimax better 2 Oxytet better 2 Both the same 4	Co-trimax better 2 Oxytet better 2 Both the same 4	**NS**
		Severity change/photo	Mid (12)	Considerable 4 Partial 2 None 2	Considerable 5 Partial 3 None 0	
		Side effects	Mid (12)	Flatulence/ abdominal pain 1 None 7	Flatulence/ abdominal pain 0 None 8	
	H.06.07			**Oxytetracycline**	**Trimethoprim**	
128 ↑ Parallel Mild N=45		**Overall change/patient**	Short (4)	Excellent 1 Good 1 Fair 18 No change 3	Excellent 0 Good 7 Fair 11 No change 3	**NS**
		Side effects	Short (4)	Worse 1 Bad enough to withdraw 0 Headache/abd pain 3 None	Worse 0 Bad enough to withdraw 2 Headache/abd pain 0 None	
		Overall change/patient	Mid (8)	Excellent 0 Good 8 Fair 15 No change 1	Excellent 2 Good 10 Fair 5 No change 3	**NS**
				Worse 0	Worse 1	
	H.07.01			**Trimethporim-sulfamethoxazole**	**Placebo**	
223 ↑ Cross-over N=40		**Dizziness and headaches**	Short (4)	Dizziness and headaches 1	Dizziness and headache 0	

TRIAL: ↑↓ -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method Info	Compar-ison	Discrete Outcome Name (Units) Definition/Comments	Follow-up (wks)	Treatment Attribute: Number of patient	Comparator Attribute: Number of patients	Between P-value
223 ↑ Cross-over N=40		**Red macular rash**	Short (4)	Macular rash (withdraw) 1 No rash 39	Macular rash (withdraw) 0 No rash 33	
	H.07.02			**Sulfadimethoxine**	**Placebo**	
41 ↑ Cross-over Sev N=134		**Inter-treatment preference/physician**	Mid (10)	More effective 75 Equally effective 37 Less effective 22	More effective 22 Equally effective 37 Less effective 75	
	H.08.01			**Tetracycline**	**Placebo**	
201 ↑ Parallel N=51		**Clinical change (grouped)**	Mid (12)	Improved 23 No change 0 Worse 1	Improved 15 No change 4 Worse 8	**0.01**
		Clinical change/photo (grouped)	Mid (12)	Improved 18 No change 5 Worse 1	Improved 9 No change 14 Worse 4	**0.01**
		Clinical improvement/photo (grouped)	Mid (12)	Improvement 13 No change 11 Worse 0	Improved 2 No change 20 Worse 5	**0.01**
		Side effects	Mid (12)	Nausea 0 Pruritis ani 0 Contact lens discomfort 1	Nausea 0 Pruritis ani 0 Contact lens discomfort 0	
	H.08.01			**Tetracycline**	**Topical treatment**	
69 ↓ Parallel N=68		**Improvement**	Long (16	Much improvement 36 Little improvement 18	Much improvement 2 Little improvement 12	
		Side effects	Long (16	Diarrhea & GI problems 2	Diarrhea & GI problems 0	
	H.08.01			**Tetracycline (oral) + vehicle (topical)**	**Vehicle (topical) + placebo (oral)**	
10 Parallel Mod N=60		**Severity change**	Mid (8)	> 1 unit decrease 12 < 1 unit decrease 1 No change 5	> 1 unit decrease 6 < 1 unit decrease 4 No change 7	**NS**
	H.08.01			**Tetracycline + vehicle**	**Vehicle (oral) + vehicle (topical)**	

TRIAL: ↑↓ -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method Info	Compar-ison	Discrete Outcome Name (Units) Definition/Comments	Follow-up (wks)	Treatment Attribute: Number of patient	Comparator Attribute: Number of patients	Between P-value
33 Parallel Mild N=87		**Diarrhea**	Mid (8)	Present 1	Present 1	
		Overall change/patient	Mid (8)	Marked improvement 11 Improved 10 No change 7 Worse 1	Marked improvement 0 Improved 1 No change 20 Worse 8	
		Overall change/physcian	Mid (8)	Excellent 11 Good 6 Fair 8 Poor 4	Excellent 0 Good 0 Fair 4 Poor 25	
	H.08.01			**Tetracycline hydrochloride**	**Vehicle**	
71 Cross-over N=150		**Severity change**	Short (4)	Worse 10 No change after good response 3 No change 6 Slight 15	Worse 10 No change after good response 2 No change 9 Slight 11	**NS**
				Good 4 Excellent 3	Good 7 Excellent 3	
		Side effects	Short (4)	Photoreactivity 3	Photoreactivity 1	
	H.08.02			**Tetracycline + vehicle**	**Clindamycin + vehicle**	
33 Parallel Mild N=87		**Diarrhea**	Mid (8)	Present 1	Present 1	
		Overall change/patient	Mid (8)	Marked improvement 11 Improved 10 No change 7 Worse 1	Marked improvement 19 Improved 3 No change 7 Worse 0	
		Overall change/physcian	Mid (8)	Excellent 11 Good 6 Fair 8 Poor 4	Excellent 17 Good 6 Fair 1 Poor 5	
	H.08.02			**Tetracycline hydrochloride + placebo**	**Clindamycin + placebo**	

TRIAL: ↑↓ -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method Info	Compar-ison	Discrete Outcome Name (Units) Definition/Comments	Follow-up (wks)	Treatment Attribute: Number of patient	Comparator Attribute: Number of patients	Between P-value
186 ↓ Parallel Mod N=44		**Side effects**		Erythema 1 Gastrointestinal upset 1 Diarrhea 1	Erythema 0 Gastro-intestinal upset 0 Diarrhea 1	
	H.08.03			**Tetracycline hydrochloride + placebo (topical)**	**Erythromycin + placebo (oral)**	
279 ↑ Parallel Mod/sev N=54		**Overall change/physician, patient**	Short (4)	Excellent 5 Good 13 Fair 6 Poor 1	Excellent 2 Good 13 Fair 8 Poor 2	
		Closed comedones severity change (vas)	Mid (12)	Worse 0 >50% reduction 6	Worse 0 >50% reduction 12	
		Open comedones severity change (vas)	Mid (12)	>50% reduction 14	>50% reduction 19	**NS**
		Overall change/physician, patient	Mid (12)	Excellent 4 Good 10 Fair 5 Poor 3	Excellent 17 Good 12 Fair 6 Poor 0	**NS**
		Papules severity change (vas)	Mid (12)	Worse 0 >50% reduction 15	Worse 0 >50% reduction 19	**NS**
		Pustules severity change (vas)	Mid (12)	>50% reduction 14	>50% reduction 20	**NS**
		Withdrawals due to side effects	Mid (12)	Withdraw 2	Withdraw 0	
	H.08.04			**Tetracycline (oral) + vehicle (topical)**	**Tetracycline (topical) + placebo (oral)**	
10 Parallel Mod N=60		**Severity change**	Mid (8)	> 1 unit decrease 12 < 1 unit decrease 1 No change 5	> 1 unit decrease 14 < 1 unit decrease 3 No change 2	**NS**
	H.08.05			**Tetracycline + placebo**	**Azelaic acid + placebo**	
22 ↓ Parallel Mod/sev N=45		**Abdominal pain**	Long (24	Present 1 Absent 21	Present 0 Absent 23	
	H.08.05			**Tetracycline hydrochloride**	**Azelaic acid + placebo**	

TRIAL: ↑↓ -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method Info	Compar-ison	Discrete Outcome Name (Units) Definition/Comments	Follow-up (wks)	Treatment Attribute: Number of patient	Comparator Attribute: Number of patients	Between P-value
166 ↑ Parallel Mild/mod N=333		**Overall change/physician**	Mid (12)	Excellent/good 127 Other 42	Excellent/good 115 Other 49	
		Overall change/physician	Long (20	Excellent/good 145 Other 24	Excellent/good 134 Other 30	**NS**
	H.08.05			**Tetracycline hydrochloride + placebo**	**Azelaic acid + placebo**	
167 ↑ Parallel Mod/sev N=261		**Overall change/patient**	Long (24	Good or excellent 82 Other 53	Good or excellent 78 Other 48	
	H.08.08			**Tetracycline**	**Tetracycline + proteolytic enzymes**	
317 ↑ Parallel Sev N=51		**Severity change**	Mid (12)	Much improved 13 Not improved 12	Much improved 18 Not improved 8	**NS**
	H.08.08			**Tetracycline (sustained release)**	**Tetracycline hydrochloride**	
212 ↑ Parallel N=55		**Overall change/physician**	Short (4)	Improved 11 No change 10 Worse 0	Improved 11 No change 5 Worse 2	**NS**
		Overall change/physician	Mid (12)	Improved 15 No change 6 Worse 0	Improved 13 No change 5 Worse 0	**NS**
		Side effects	Mid (12)	Diarrhea 1 Sore mouth 1	Diarrhea 0 Sore mouth 0	
	H.08.085			**Tetracycline + sodium novobiocin**	**Placebo**	
299 ↑ Parallel Mod/sev N=42		**Overall change/physician**	Short (4)	Improved 18 Not improved 5	Improved 9 Not improved 10	**0.04**

TRIAL: ↑↓ -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method Info	Compar-ison	Discrete Outcome Name (Units) Definition/Comments	Follow-up (wks)	Treatment Attribute: Number of patient	Comparator Attribute: Number of patients	Between P-value
299 ↑ Parallel Mod/sev N=42		**Side effects**	Short (4)	Diarrhea 0	Diarrhea 1	
				Dryness of oral mucous 0	Dryness of oral mucous 1	
				Headache 1	Headache 0	
				Low seeing theshold 1	Low seeing theshold 0	
				Macular drug reaction 1	Macular drug reaction 0	
	H.08.14			**Povidone-iodine + tetracycline**	**Tetracycline + vehicle**	
236 ↓ Parallel Mod/sev N=30		**Itching**	Long (14	Itching 0	Itching 0	
		Overall change/physician	Long (14	Improved or much improved 10	Improved or much improved 12	
				No change or worse 3	No change or worse 2	
	H.09.01			**Dapsone**	**Placebo**	
293 ↑ Parallel Mild/mod/sev N=46		**Severity change**		Greatly improved 9	Greatly improved 3	**0.05**
				Improved 3	Improved 2	
				Not improved 9	Not improved 18	
		Severity change [female]		Greatly improved 5	Greatly improved 1	**0.01**
				Improved 2	Improved 1	
				Not improved 2	Not improved 14	
		Severity change [male]		Greatly improved 4	Greatly improved 2	
				Improved 1	Improved 1	
				Not improved 7	Not improved 4	
		Side effects		Present 6	Present 3	
		Side effects [Female]		Present 4	Present 0	**0.1**
		Side effects [Male]		Present 2	Present 3	
	H.09.02			**Phenethicillin**	**Placebo**	
312 ↑ Parallel Mild/mod/sev N=66		**Overall change/physician**	Short (4)	Improved 5	Improved 3	**NS**
				No change 10	No change 13	
				Worse 1	Worse 0	
				Not assessed 4	Not assessed 6	
	H.09.04			**Sodium fusidate (oral)**	**Sodium fusidate (topical)**	

TRIAL: ↑↓ -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method Info	Compar-ison	Discrete Outcome Name (Units) Definition/Comments	Follow-up (wks)	Treatment Attribute: Number of patient	Comparator Attribute: Number of patients	Between P-value
344 ↑ Parallel Mild/mod/sev N=70		**Overall change/physician**	Short (2)	No effect 14 Improved 22 Completely resolved 1	No effect 13 Improved 18 Completely resolved 0	
		Severity change/photo	Short (2)	Improved 11 Worse 6 No difference 19	Improved 11 Worse 2 No difference 15	
		Side effects	Short (2)	Gastric irritation 7	Gastric irritation 0	

TRIAL: ↑↓ -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN P-VALUE: comparison between Target and Comparator arms.